Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4697 - Genetic signatures always suggest undertreatment? Experience with PAM51

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Carolina Sales

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

C. Sales1, I. Vieira1, M. Cassiano1, C. Oliveira1, C. Vieira1, M. Ferreira1, A. Rodrigues1, A. Ferreira1, M.I. Pousa1, R. Couto1, C. Leal2, J. Abreu3, M. Teixeira4, D. Pereira1, S. Sousa1, M.H. Abreu1

Author affiliations

  • 1 Medical Oncology, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), 4200-072 - Porto/PT
  • 2 Pathology, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), 4200-072 - Porto/PT
  • 3 Surgical oncology, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), 4200-072 - Porto/PT
  • 4 Clinical Genetics, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), 4200-072 - Porto/PT
More

Resources

Abstract 4697

Background

PAM50 (Prosigna®) identifies a gene-expression profile that categorises early breast cancer (BC) in intrinsic subtypes and gives prognostic estimation based on a 10 year-recurrence risk score (ROR). The purpose of this study was to evaluate the impact of PAM50's information on adjuvant treatment decisions.

Methods

Prospective collection of BC cases treated in a Cancer Centre in the last 10 months, in which PAM50 was used to define treatment strategy. Demographic, clinic and pathologic characteristics are described. Concordance between immunohistochemistry (IHC) and PAM50 subtypes were assessed as well as therapeutic decision changes according to risk stratification, using blind revision. Categorical variables were compared used chi-square test.

Results

Inclusion of 101 patients, median age of 52 years (34-79 years). Fifty-five patients (54.5%) were premenopausal, 71 (70.3%) had ductal carcinomas, 71 (70.3%) pT1c, 99 (98%) G2, 72 (71.3%) pN0, ER positive and HER2 negative. Eighty five(84.2%) had a PR expression above 20% and 63 (62.4%) had a Ki67≤15%. Overall discordance rate between BC subtypes by IHQ and PAM50 was 34%, (p < 0.001). By IHC, 51 (50.5%) were luminal A-like. Forty seven(92%) remained luminal A with PAM 50 [(low ROR: 28 (60%), intermediate:16 (34%), high:3 (6%)]. Four (8%) changed to luminal B [intermediate ROR:1 (25%), high:3 (75%)]. Of the 50 luminal B-like tumours (49.5%), 20 (40%) remained luminal B [intermediate ROR: 8 (40%); high:12 (60%)] and 30 (60%) changed to luminal A [low ROR:18 (60%), intermediate:12 (40%)]. Based on PAM50, adjuvant strategy was changed in 28 patients (28%), (p = 0.001): 15 (54%) changed from endocrine therapy (ET) only to chemotherapy (CT) also and 13 (46%) changed from CT and ET to ET only.

Conclusions

PAM50 availability results in 28% change in adjuvant plan with more cases of chemotherapy. The 34% discordance with classic IHC subgroups, especially in luminal B tumours, underlines the need for more accurate tests in this heterogeneous population to define the adequate adjuvant strategy. A longer follow up is important to evaluate the prognostic value of clinical decisions based on genetic signatures.

Clinical trial identification

Legal entity responsible for the study

Breast Department - IPO-Porto.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings